379 related articles for article (PubMed ID: 18663562)
1. Comparison of FDG PET and MRI for evaluating the tumor extent of breast cancer and the impact of FDG PET on the systemic staging and prognosis of patients who are candidates for breast-conserving therapy.
Uematsu T; Kasami M; Yuen S
Breast Cancer; 2009; 16(2):97-104. PubMed ID: 18663562
[TBL] [Abstract][Full Text] [Related]
2. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
3. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
[TBL] [Abstract][Full Text] [Related]
4. Preoperative staging of liver metastases from uveal melanoma by magnetic resonance imaging (MRI) and fluorodeoxyglucose-positron emission tomography (FDG-PET).
Servois V; Mariani P; Malhaire C; Petras S; Piperno-Neumann S; Plancher C; Levy-Gabriel C; Lumbroso-le Rouic L; Desjardins L; Salmon RJ
Eur J Surg Oncol; 2010 Feb; 36(2):189-94. PubMed ID: 19775851
[TBL] [Abstract][Full Text] [Related]
5. [Performance of 18F-FDG PET/CT in the detection of primary breast cancer and staging of the regional lymph nodes].
Zhao TT; Li JG; Li YM
Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):206-9. PubMed ID: 17649638
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT.
Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E; Ebied O
Eur J Radiol; 2009 Jun; 70(3):530-8. PubMed ID: 18395387
[TBL] [Abstract][Full Text] [Related]
7. A treatment selection protocol for recurrent ovarian cancer patients: the role of FDG-PET/CT and staging laparoscopy.
Fagotti A; Fanfani F; Rossitto C; Lorusso D; De Gaetano AM; Giordano A; Vizzielli G; Scambia G
Oncology; 2008; 75(3-4):152-8. PubMed ID: 18827492
[TBL] [Abstract][Full Text] [Related]
8. The Role of 18F-FDG PET/CT in the evaluation of Ascites of Undetermined Origin.
Zhang M; Jiang X; Zhang M; Xu H; Zhai G; Li B
J Nucl Med; 2009 Apr; 50(4):506-12. PubMed ID: 19289438
[TBL] [Abstract][Full Text] [Related]
9. Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer.
Groheux D; Moretti JL; Baillet G; Espie M; Giacchetti S; Hindie E; Hennequin C; Vilcoq JR; Cuvier C; Toubert ME; Filmont JE; Sarandi F; Misset JL
Int J Radiat Oncol Biol Phys; 2008 Jul; 71(3):695-704. PubMed ID: 18436392
[TBL] [Abstract][Full Text] [Related]
10. Breast magnetic resonance imaging for preoperative locoregional staging.
Hollingsworth AB; Stough RG; O'Dell CA; Brekke CE
Am J Surg; 2008 Sep; 196(3):389-97. PubMed ID: 18436185
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of dual-time-point 18F-FDG PET for staging in patients with lung cancer.
Uesaka D; Demura Y; Ishizaki T; Ameshima S; Miyamori I; Sasaki M; Fujibayashi Y; Okazawa H
J Nucl Med; 2008 Oct; 49(10):1606-12. PubMed ID: 18794269
[TBL] [Abstract][Full Text] [Related]
12. Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma.
Tateishi U; Hosono A; Makimoto A; Nakamoto Y; Kaneta T; Fukuda H; Murakami K; Terauchi T; Suga T; Inoue T; Kim EE
Ann Nucl Med; 2009 Feb; 23(2):155-61. PubMed ID: 19225939
[TBL] [Abstract][Full Text] [Related]
13. Improved detection of breast cancer on FDG-PET cancer screening using breast positioning device.
Kaida H; Ishibashi M; Fujii T; Kurata S; Ogo E; Tanaka M; Hayabuchi N
Ann Nucl Med; 2008 Feb; 22(2):95-101. PubMed ID: 18311533
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer.
Kumar R; Chauhan A; Zhuang H; Chandra P; Schnall M; Alavi A
Breast Cancer Res Treat; 2006 Aug; 98(3):267-74. PubMed ID: 16555126
[TBL] [Abstract][Full Text] [Related]
15. Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer--usefulness for malignant grade of triple-negative breast cancer.
Ohara M; Shigematsu H; Tsutani Y; Emi A; Masumoto N; Ozaki S; Kadoya T; Okada M
Breast; 2013 Oct; 22(5):958-63. PubMed ID: 23756383
[TBL] [Abstract][Full Text] [Related]
16. Comparison of 4 modalities for distant metastasis staging in endemic nasopharyngeal carcinoma.
Chua ML; Ong SC; Wee JT; Ng DC; Gao F; Tan TW; Fong KW; Chua ET; Khoo JB; Low JS
Head Neck; 2009 Mar; 31(3):346-54. PubMed ID: 18972431
[TBL] [Abstract][Full Text] [Related]
17. Preoperative risk stratification using (18)F-FDG PET/CT in women with endometrial cancer.
Lee HJ; Ahn BC; Hong CM; Song BI; Kim HW; Kang S; Jeong SY; Lee SW; Lee J
Nuklearmedizin; 2011; 50(5):204-13. PubMed ID: 21727990
[TBL] [Abstract][Full Text] [Related]
18. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
De Giorgi U; Valero V; Rohren E; Dawood S; Ueno NT; Miller MC; Doyle GV; Jackson S; Andreopoulou E; Handy BC; Reuben JM; Fritsche HA; Macapinlac HA; Hortobagyi GN; Cristofanilli M
J Clin Oncol; 2009 Jul; 27(20):3303-11. PubMed ID: 19451443
[TBL] [Abstract][Full Text] [Related]
19. 18-fluoro-2-deoxyglucose positron emission tomography in detecting residual/recurrent nasopharyngeal carcinomas and comparison with magnetic resonance imaging.
Yen RF; Hung RL; Pan MH; Wang YH; Huang KM; Lui LT; Kao CH
Cancer; 2003 Jul; 98(2):283-7. PubMed ID: 12872346
[TBL] [Abstract][Full Text] [Related]
20. FDG-PET-CT for staging of high-risk breast cancer patients reduces the number of further examinations: A pilot study.
Jager JJ; Keymeulen K; Beets-Tan RG; Hupperets P; van Kroonenburgh M; Houben R; de Ruysscher D; Lambin P; Boersma LJ
Acta Oncol; 2010; 49(2):185-91. PubMed ID: 20017664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
